Thu.May 23, 2024

article thumbnail

Slideshow: Mental Health Burden of Food Allergy, Nutritional Intervention May Help Children

Drug Topics

Recent research on food allergy highlights the mental health concerns of people living with a food allergy, how nutritional intervention can help children with food allergy, and that peanut introduction can reduce rates of new allergy in high-risk infants.

244
244
article thumbnail

Optimizing Pharmaceutical Innovation Through AI: A Pathway to Expedited Drug Discovery and Development

Pharmacy Times

Clinical trials are using AI to handle large and complex volumes of data to develop oncology, cardiovascular, and neurologic compounds and to integrate molecular and imaging data.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Obesity is Common in Individuals with Celiac Disease

Drug Topics

In an abstract presented at Digestive Disease Week 2024, researchers analyzed the prevalence of obesity in patients with and without celiac disease.

232
232
article thumbnail

Counsel Patients on Nutrition and Following a Balanced Diet Complementary to GLP-1s

Pharmacy Times

The GLP-1 market is expected to exceed $100 billion by 2023, according to J.P. Morgan Research, with total users in the United States projected to reach 30 million.

158
158
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Q&A: What Pharmacists Need to Know About Tianeptine

Drug Topics

Savannah Roberts Clary, PharmD, BCPS, CPGx, a clinical pharmacist with Aegis Sciences Corporation, discusses what tianeptine is and how pharmacists can help warn the public about its potential hazards.

177
177
article thumbnail

Sotorasib Plus Panitumumab Significantly Improves Outcomes in Colorectal Cancer

Pharmacy Times

Combination treatment of sotorasib plus panitumumab prolongs progression-free survival in those with metastatic colorectal cancer and the KRAS G12C mutation.

148
148

More Trending

article thumbnail

New data show the HPV vaccine prevents cancer in men, too. Why don’t more people get it?

STAT

You’d think if there were a vaccine that would prevent tens of thousands of cases of cancer a year, people would want it for themselves and for their kids. But new data being released Thursday ahead of the annual meeting of the American Society of Clinical Oncology show that just isn’t the case.

Vaccines 145
article thumbnail

Public Health Matters: Getting Involved With State Pharmacy Associations, Advocating for Pharmacists, Promoting Professional Development

Pharmacy Times

Tune into this episode of “Public Health Matters” to hear Dr. Kate Gainer’s journey in state pharmacy association and how advocacy and legislative initiatives can benefit pharmacists.

134
134
article thumbnail

At long last, AstraZeneca, Pfizer, J&J, Roche and others have an ally in Biden

Fierce Pharma

Over the last four years, with President Joe Biden milking a popular cause as an opponent of Big Pharma drug pricing, the industry has rarely seen good news coming from the White House. | Over the last four years, with President Joe Biden milking a popular cause as an opponent of Big Pharma's pricing, the industry has rarely seen good news coming from the White House.

128
128
article thumbnail

Nurturing Fertility: Pharmacist's Insights for Women's Health Awareness Month

Pharmacy Times

Fertility pharmacists understand the importance of education, awareness, and support women need to discover in navigating the complexities of fertility.

132
132
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

Reversing progress, stroke rates are rising, especially in working-age adults

STAT

Stroke prevalence has been climbing over the past decade, reversing a steady decline among all Americans while rising the most among adults under 65, a new CDC analysis reports. Strokes still strike more adults older than 65, but the increase at younger ages mirrors another recent turnaround: rates of heart failure deaths, which had been dipping, are rising the most in adults under 45.

120
120
article thumbnail

The 20 highest paid specialties in 2023 as doctors see 6% boost in pay: Doximity

Fierce Healthcare

After several years of modest or declining growth, the average pay for doctors jumped 5.9% in 2023, rebounding from a decline of 2.4% in 2022. | After several years of modest or declining growth, the average pay for doctors jumped 5.9% in 2023, rebounding from a decline of 2.4% in 2022.

118
118
article thumbnail

ASCO: Bristol Myers unveils I-O triplet data in melanoma as Iovance touts ‘paradigm-changing’ combo result

Fierce Pharma

Over the years, melanoma has become a popular testing ground for researchers to explore new immuno-oncology approaches. | With prior approvals in melanoma, Bristol Myers Squibb and Iovance are now showcasing early clinical data for their novel combinations in small first-line melanoma trials.

118
118
article thumbnail

Opinion: Addressing health care workers’ trauma can help fight burnout

STAT

Burnout is a growing crisis in health care: More than 50% of health care professionals report symptoms of it. Addressing the trauma they face at work can help. Halting burnout straddles the tension between addressing the individual factors versus the organizational factors behind it. It was once believed that burnout was related to health workers’ inability to cope with the natural stresses of their job.

118
118
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Five Unexpected New Uses for GLP-1 Receptor Agonists

Pharmacy Times

Data have shown the potential for the therapy to treat several new conditions.

160
160
article thumbnail

STAT+: FDA advisers endorse Guardant Health’s colon cancer screening test

STAT

An independent panel of advisers to the Food and Drug Administration recommended the agency approve Guardant Health’s blood-based colon cancer detection test. If the agency follows the recommendation, it will clear an early hurdle for the test’s broader adoption. The expert panel spent hours listening to presentations from Guardant, the FDA, and members of the public before voting on the screening test, called Shield.

FDA 115
article thumbnail

Cytokinetics eyes go-it-alone strategy for aficamten

pharmaphorum

Cytokinetics has been a top biotech takeover candidate for some time, thanks to blockbuster speculation about its lead drug aficamten, but a $1 billion-plus set of financing deals shows it is prepared to go to market on its own.

111
111
article thumbnail

Opinion: Making the case for fair compensation in clinical trials

STAT

I’ve been on three sides of the health care equation: I’ve beaten stage 4 colorectal cancer, I’m the mother of a son with an ultra-rare genetic abnormality, and I now work as the chief patient officer for Parexel, one of the world’s largest clinical research organizations. Having seen what people go through as they navigate the health care system and try to participate in clinical trials, I know that the road to participation must be smoother and easier — and n

114
114
article thumbnail

Centene taps McCormack Baron Salazar for investments in affordable housing

Fierce Healthcare

Centene's philanthropic arm is joining forces with McCormack Baron Salazar to develop new affordable housing options in multiple states. | Centene's philanthropic arm is joining forces with McCormack Baron Salazar to develop new affordable housing options in multiple states.

108
108
article thumbnail

In light of H5N1 outbreak, U.S. in talks with mRNA vaccine makers on bird flu

STAT

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Good morning. Wall Street had a big reaction to H5N1 bird flu news yesterday. Was it warranted? We’ll discuss that today.

Vaccines 112
article thumbnail

J&J faces allegations it used 'fraudulent maneuvers' to avoid compensating talc plaintiffs

Fierce Pharma

As Johnson & Johnson sorts through a mountain of litigation claiming its talcum-based powders caused users to develop cancers, the company has now been slapped with a related but different | Women represented by six law firms who previously filed lawsuits against J&J over talc claims have filed a proposed class action lawsuit in U.S. federal court in New Jersey.

106
106
article thumbnail

Collaboration is key to tackling geographical boundaries in CGT development

pharmaphorum

Collaboration is the key to unlocking the potential of cell and gene therapies (CGTs) across geographical boundaries. Explore how autologous treatments are shaping the future of this cutting-edge medical field.

106
106
article thumbnail

Atropos Health lands $33M to scale AI-powered real-world evidence, build out pharma partnerships

Fierce Healthcare

Atropos Health, maker of a real-world data platform, sits at the intersection of two rapidly growing fields, real-world evidence research and artificial intelligence. | Atropos Health is getting closer to its mission of addressing the evidence gap in healthcare and secured $33 million in series B funding to help fuel its growth.

104
104
article thumbnail

Second fire at Novo Nordisk in a week now under control

pharmaphorum

Novo Nordisk’s second facility fire in a week is under control, although the office in Bagsvaerd affected by the latest blaze isn’t expected to be salvageable.

111
111
article thumbnail

Biogen Agrees to Acquire HI-BIO for $1.15 Billion

Pharmaceutical Commerce

The deal features felzartamab, an investigational anti-CD38 monoclonal antibody, whose clinical outcomes have shown potential to tackle various immune-mediated diseases.

article thumbnail

Merck builds in cell, gene therapies with Mirus Bio deal

pharmaphorum

Merck KGaA has agreed to a $600m deal to buy Mirus Bio, a specialist in transfection reagents used in the production of cell and gene therapies.

115
115
article thumbnail

Progressing catheter insertion: A breakthrough in ultrasound guidance technology

Outsourcing Pharma

Continuing the Montreal startup ideas presented to OSP and others during a recent trip, this was another idea to come from Centech, the non-profit organization helping people develop their ideas in a bid to making them a reality.

98
article thumbnail

Biogen bets $1.15bn on immunology drug developer HI-Bio

pharmaphorum

Biogen has expanded its specialty immunology pipeline with an agreement to buy Human Immunology Biosciences (HI-Bio) and its lead drug felzartamab, in trials for a range of diseases including IgA nephropathy (IgAN).

102
102
article thumbnail

STAT+: Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again, and other thoughts

STAT

Thoughts about Cytokinetics after Wednesday night’s financing announcement : 1. Management is raising $500 million at $51 per share, when the stock was at $45 per share before the aficamtem study readout in December. That’s shocking. Somehow, management has not only removed all the M&A premium from the stock, but much or most of aficamtem’s value, too. 2.

97
article thumbnail

Which companies will last? Success begins with the basics

pharmaphorum

In the post-COVID world, which start-ups will thrive and which will fizzle? Discover the fundamental strategies that separate the winners from the losers.

110
110
article thumbnail

AstraZeneca and Nona Biosciences sign agreement for monoclonal antibody

Pharmaceutical Technology

AstraZeneca has entered into a worldwide licence and option agreement with Nona Biosciences for a preclinical monoclonal antibody.

115
115
article thumbnail

Chinese firm throws lifeline to Pfizer UK plant workers

pharmaphorum

China’s Asymchem Laboratories has agreed to take over the operation of a Pfizer manufacturing facility in Sandwich, UK, saving dozens of jobs.

111
111
article thumbnail

What can pharma companies do to get promising antimicrobials to the frontlines of drug resistance?

Outsourcing Pharma

A new report from Access to Medicine Foundation gives the advice to ensure the few promising antimicrobials in development reach patients on the frontlines of drug resistance.

96
article thumbnail

STAT+: Ahead of ASCO, J&J reports mixed data on next-generation radiopharmaceutical

STAT

An early-stage clinical trial of a radiopharmaceutical drug developed by Johnson & Johnson showed some signs of efficacy in prostate cancer patients, newly released data show, but four participants in the trial died. The drug, JNJ-6420, is designed to treat metastatic castration-resistant prostate cancer by delivering radioactive isotopes directly to cancer cells.

90